Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma

Trogenix announced the first patient dosing in its Phase I/II ADePT clinical trial evaluating TGX-007, a dual-payload AAV gene therapy for glioblastoma. The trial is being conducted at NHS Lothian (UK) and Ohio State University Hospital (USA). The therapy uses Trogenix's proprietary Synthetic Super-Enhancer technology to deliver two therapeutic payloads with precision to tumor cells. Pre-clinical data published in Nature showed 83% complete tumor eradication with no toxicity over 11 months.